Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort

and the; AIBL Research Group

doi:10.1016/j.dadm.2017.04.003

Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort

and the, AIBL Research Group

Research output: Contribution to journal › Article

7 Scopus citations

Abstract

Introduction A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. Methods We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. Results Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P =.0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P =.0008). Discussion These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.

Original language	English
Pages (from-to)	60-72
Number of pages	13
Journal	Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
Volume	8
DOIs	https://doi.org/10.1016/j.dadm.2017.04.003
State	Published - 2017

Keywords

Alzheimer's disease
Biomarkers
Blood

Access to Document

10.1016/j.dadm.2017.04.003

Link to publication in Scopus

Fingerprint Dive into the research topics of 'Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort'. Together they form a unique fingerprint.

Cite this

and the, & AIBL Research Group (2017). Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 8, 60-72. https://doi.org/10.1016/j.dadm.2017.04.003

@article{1c6cf48d5aa94fd48af4654611dd49e8,

title = "Altered levels of blood proteins in Alzheimer's disease longitudinal study: Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort",

abstract = "Introduction A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. Methods We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. Results Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P =.0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P =.0008). Discussion These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.",

keywords = "Alzheimer's disease, Biomarkers, Blood",

author = "{and the} and {AIBL Research Group} and Gupta, {Veer Bala} and Eugene Hone and Steve Pedrini and James Doecke and Sid O'Bryant and Ian James and Bush, {Ashley I.} and Rowe, {Christopher C.} and Villemagne, {Victor L.} and David Ames and Masters, {Colin L.} and Martins, {Ralph N.}",

year = "2017",

doi = "10.1016/j.dadm.2017.04.003",

language = "English",

volume = "8",

pages = "60--72",

journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",

issn = "2352-8729",

publisher = "Elsevier BV",

}

TY - JOUR

T1 - Altered levels of blood proteins in Alzheimer's disease longitudinal study

T2 - Results from Australian Imaging Biomarkers Lifestyle Study of Ageing cohort

AU - and the

AU - AIBL Research Group

AU - Gupta, Veer Bala

AU - Hone, Eugene

AU - Pedrini, Steve

AU - Doecke, James

AU - O'Bryant, Sid

AU - James, Ian

AU - Bush, Ashley I.

AU - Rowe, Christopher C.

AU - Villemagne, Victor L.

AU - Ames, David

AU - Masters, Colin L.

AU - Martins, Ralph N.

PY - 2017

Y1 - 2017

N2 - Introduction A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. Methods We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. Results Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P =.0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P =.0008). Discussion These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.

AB - Introduction A blood-based biomarker panel to identify individuals with preclinical Alzheimer's disease (AD) would be an inexpensive and accessible first step for routine testing. Methods We analyzed 14 biomarkers that have previously been linked to AD in the Australian Imaging Biomarkers lifestyle longitudinal study of aging cohort. Results Levels of apolipoprotein J (apoJ) were higher in AD individuals compared with healthy controls at baseline and 18 months (P =.0003) and chemokine-309 (I-309) were increased in AD patients compared to mild cognitive impaired individuals over 36 months (P =.0008). Discussion These data suggest that apoJ may have potential in the context of use (COU) of AD diagnostics, I-309 may be specifically useful in the COU of identifying individuals at greatest risk for progressing toward AD. This work takes an initial step toward identifying blood biomarkers with potential use in the diagnosis and prognosis of AD and should be validated across other prospective cohorts.

KW - Alzheimer's disease

KW - Biomarkers

KW - Blood

UR - http://www.scopus.com/inward/record.url?scp=85018739152&partnerID=8YFLogxK

U2 - 10.1016/j.dadm.2017.04.003

DO - 10.1016/j.dadm.2017.04.003

M3 - Article

AN - SCOPUS:85018739152

VL - 8

SP - 60

EP - 72

JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

SN - 2352-8729

ER -